Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 11 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

The Effects of an Nutritional Intervention on PD-1 ICI in NSCLCCompletedNCT05902260Not applicable Report a problem
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive, not recruitingNCT05899049Phase 3 Report a problem
TEIPP Immunotherapy in Patients With NSCLCCompletedNCT05898763Phase 1/2 Report a problem
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLCActive, not recruitingNCT05894889Phase 2 Report a problem
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial CancersWithdrawnNCT05894447Phase 1 Report a problem
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsActive, not recruitingNCT05887492Phase 1/2 Report a problem
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnNCT05879484Phase 1/2 Report a problem
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent GlioblastomaWithdrawnNCT05879120Phase 2 Report a problem
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.Active, not recruitingNCT05878691Phase 1 Report a problem
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung CancersTerminatedNCT05860296Phase 1/2 Report a problem
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid TumorsTerminatedNCT05859464Phase 1 Report a problem
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)Active, not recruitingNCT05853367Phase 1 Report a problem
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)Active, not recruitingNCT05845814Phase 1/2 Report a problem
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerActive, not recruitingNCT05843448Phase 1 Report a problem
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.Active, not recruitingNCT05838768Phase 1 Report a problem
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated CancerCompletedNCT05826275Phase 1 Report a problem
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Active, not recruitingNCT05816252Phase 2 Report a problem
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid TumorsCompletedNCT05809336Phase 2/3 Report a problem
Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T LymphocytesCompletedNCT05792995Phase 2 Report a problem
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)Active, not recruitingNCT05787639Phase 2 Report a problem
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsActive, not recruitingNCT05787587Phase 1 Report a problem
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid TumorsCompletedNCT05763004Phase 1 Report a problem
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial CancerActive, not recruitingNCT05761951Phase 2 Report a problem
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced MalignanciesCompletedNCT05753722Phase 1 Report a problem
PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell CarcinomaWithdrawnNCT05743777Phase 2 Report a problem
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT05721755Phase 3 Report a problem
IMM60 and Pembrolizumab in Melanoma and NSCLCTerminatedNCT05709821Phase 1/2 Report a problem
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)CompletedNCT05708950Phase 1/2 Report a problem
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung CancerWithdrawnNCT05705466Phase 1/2 Report a problem
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsActive, not recruitingNCT05704985Phase 1 Report a problem
C-TIL051 in Non-Small Cell Lung CancerTerminatedNCT05676749Phase 1 Report a problem
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerSuspendedNCT05673200Phase 1 Report a problem
CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain MetastasesSuspendedNCT05669352Phase 1/2 Report a problem
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT05668949Phase 1/2 Report a problem
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsActive, not recruitingNCT05653882Phase 1 Report a problem
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid TumorsActive, not recruitingNCT05642780Phase 2 Report a problem
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerActive, not recruitingNCT05620134Phase 1/2 Report a problem
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid TumorsActive, not recruitingNCT05614102Phase 1 Report a problem
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Phase 3 Report a problem
Electroporation and Immunotherapy in Metastatic Colorectal CancerTerminatedNCT05609656Phase 2 Report a problem
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationActive, not recruitingNCT05609578Phase 2 Report a problem
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Active, not recruitingNCT05599789Phase 2 Report a problem
Study of DF9001 in Patients With Advanced Solid TumorsCompletedNCT05597839Phase 1/2 Report a problem
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/2 Report a problem
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsCompletedNCT05585034Phase 1 Report a problem
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT05581004Phase 1 Report a problem
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT05576077Phase 1 Report a problem
CISH Inactivated TILs in the Treatment of NSCLCWithdrawnNCT05566223Phase 1/2 Report a problem
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)Active, not recruitingNCT05562830Phase 1/2 Report a problem
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT05558982Phase 2 Report a problem
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Active, not recruitingNCT05555732Phase 3 Report a problem
Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy FailureStatus unknownNCT05547282Not applicable Report a problem
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1 Report a problem
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast CancerWithdrawnNCT05539365Phase 2 Report a problem
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsActive, not recruitingNCT05537740Phase 1 Report a problem
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)TerminatedNCT05525455Phase 1/2 Report a problem
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)WithdrawnNCT05518032Phase 2 Report a problem
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialActive, not recruitingNCT05514990Phase 1/2 Report a problem
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)CompletedNCT05514444Phase 1 Report a problem
A Phase 1 Study of ASKG315 in Patients With Advanced Solid TumorsStatus unknownNCT05509985Phase 1 Report a problem
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid TumorsCompletedNCT05508100Phase 1 Report a problem
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT05507541Phase 2 Report a problem
Study of KBA1412 in Participants With Advanced Solid Malignant TumorsCompletedNCT05501821Phase 1 Report a problem
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)WithdrawnNCT05487859Phase 2 Report a problem
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant GliomaActive, not recruitingNCT05484622Phase 1 Report a problem
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsCompletedNCT05479812Phase 1 Report a problem
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian CancerActive, not recruitingNCT05467670Phase 2 Report a problem
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05465954Phase 2 Report a problem
Surgical Pembro +/- Olaparib w TMZ for rGBMActive, not recruitingNCT05463848Phase 2 Report a problem
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerActive, not recruitingNCT05446298Phase 2 Report a problem
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsActive, not recruitingNCT05438420Phase 1/2 Report a problem
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid TumorsActive, not recruitingNCT05438329Phase 1/2 Report a problem
Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point InhibitorTerminatedNCT05436990Phase 2 Report a problem
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCCActive, not recruitingNCT05433116Phase 2 Report a problem
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid TumorsWithdrawnNCT05431582Phase 1 Report a problem
A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal MelanomaCompletedNCT05420324Phase 2 Report a problem
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair SystemWithdrawnNCT05419817Phase 2 Report a problem
A Study of NI-1801 in Patients with Mesothelin Expressing Solid CancersStatus unknownNCT05403554Phase 1 Report a problem
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT05395052Phase 1 Report a problem
ITIL-168 in Advanced Solid TumorsWithdrawnNCT05393635Phase 1 Report a problem
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT05386056Phase 2 Report a problem
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)TerminatedNCT05382325Phase 1 Report a problem
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382286Phase 3 Report a problem
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With PembrolizumabActive, not recruitingNCT05378425Phase 1 Report a problem
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate CancerTerminatedNCT05369000Phase 1 Report a problem
Seleno-L Methionine (SLM)-Axitinib-PembrolizumabCompletedNCT05363631Phase 1/2 Report a problem
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint InhibitorActive, not recruitingNCT05359445Phase 1 Report a problem
Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingNCT05358938Early Phase 1 Report a problem
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsTerminatedNCT05357898Phase 1/2 Report a problem
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingNCT05349890Phase 1 Report a problem
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid TumorsTerminatedNCT05346484Phase 1 Report a problem
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)CompletedNCT05342636Phase 1/2 Report a problem
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesTerminatedNCT05341349Phase 1 Report a problem
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver TransplantationStatus unknownNCT05339581Not applicable Report a problem
Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid TumorsWithdrawnNCT05338580Phase 2 Report a problem
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung CancerActive, not recruitingNCT05318573Phase 2 Report a problem
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05311618Phase 1 Report a problem
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic MelanomaCompletedNCT05309421Phase 2 Report a problem
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid TumorsCompletedNCT05309187Phase 1 Report a problem
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid TumorsTerminatedNCT05307874Phase 1/2 Report a problem

← Pembrolizumab